USPTO serial 79347429
EPIMOGRIFY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 6, 2024
- Examiner
- JANSON, ANDREW KYLE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with EPIMOGRIFY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Rebecca Liebowitz
Rebecca Liebowitz Venable LLPP.O. Box 34385Washington, DC 20043-9998UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Reagents for research purposes; molecular biology research tools in the nature of biological, chemical and biochemical reagents for scientific and research use; chemical substances, namely transcription factors and ligands for scientific and industrial use; cells for scientific and research use | ACTIVE | — |
| 005 | Medical and veterinary preparations for therapeutic purposes, namely pharmaceutical, biopharmaceutical and veterinary preparations for use in maintaining cell identity and to support the reprogramming of cells in chemically defined media; pharmaceutical and biopharmaceutical preparations for cell and gene therapy; biological preparations for modifying human or animal cells for medical or therapeutic purposes, namely, transcription factors, ligands and cell surface receptors for use in maintaining cell identity and to support the reprogramming of cells in chemically defined media; biological, chemical and biochemical reagents for medical use; cells for medical or clinical use; vaccines | ACTIVE | — |
| 009 | Downloadable bioinformatics software for epigenomic data analysis; downloadable computer software platforms for epigenomic data analysis in the field of cell and gene therapies; downloadable bioinformatics computer software platforms for epigenomic data analysis in the field of cell and gene therapies; scientific apparatus for measuring and analysing scientific study data, namely, apparatus for recording, transmission or reproduction of data, video, audio, images and text; data analysis apparatus,namely, data processing equipment and computers and downloadable operating computer software sold as a unit; downloadable scientific data analysis software | ACTIVE | — |
| 040 | Treatment and processing of biological materials, namely cells, stem cells, induced pluripotent stem cells; custom manufacture of therapeutic drugs; custom manufacture of transcription factors, ligands, cell surface receptors, cells, cell therapies and gene therapies; information, advisory and consultancy services in relation to all of the aforesaid services | ACTIVE | — |
| 042 | Scientific and technological services namely research and design analysis in the field of cell and gene therapies; industrial research services in the field of cell and gene therapies; medical and veterinary research services namely, the manipulation of cells within a laboratory or research facility to enable the cells to be used for medical or therapeutic purposes; scientific research in human and animal cell therapy and gene therapy; scientific research into preparations for manipulating and adapting human and animal cells; design and development of new products for others; scientific laboratory services; medical laboratory services; medical research laboratory services, in the field of cell and gene therapies; software as a service (SaaS) services featuring software for use in epigenomic data analysis; platform as a service (Paas) services featuring a bioinformatics software platform for use in manufacturing therapeutics; providing an online non-downloadable bioinformatics software platform for identifying transcription factors, ligands and cell surface receptors to turn one cell type into another cell type; providing an online non-downloadable bioinformatics platform for identifying transcription factors, ligands and cell surface receptors to maintain cell conversion; advisory and consultancy relating to all the aforesaid services | ACTIVE | — |
| 044 | Medical services; veterinary services; medical services for the treatment of conditions of the human or animal body; cell and gene therapy services, namely, manipulation of human and animal cells for therapeutic purposes; medical services, namely, reinsertion of cells into human and animal patients for therapeutic purposes; providing advice and consultancy in the field of medical and veterinary therapies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Mogrify Limited
- Other trademarks owned by Mogrify Limited
- Other trademarks owned by Mogrify Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named EPIMOGRIFY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 2, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 9, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 9, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 6, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 13, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 6, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 6, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 24, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 24, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 21, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 21, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 21, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 1, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 1, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 1, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 18, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 18, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 18, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 18, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 18, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 16, 2023 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Oct 16, 2023 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 16, 2023 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 7, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 7, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 7, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 6, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 10, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 10, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 18, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 17, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 4, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 23, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 19, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 18, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |